Overview

Kineret in the Treatment of Rheumatoid Arthritis

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Objective of the study is to gain knowledge about the administration of Kineret in patients with rheumatoid arthritis in the daily routine treatment and not in controlled trials. In the current survey, the investigation of the response rate of Kineret regarding the date of onset of action, the efficacy, as well as the tolerability and safety are of particular interest.
Details
Lead Sponsor:
Swedish Orphan Biovitrum
Treatments:
Interleukin 1 Receptor Antagonist Protein